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Abstract
Background: Visceral leishmaniasis (VL) is a neglected tropical disease transmitted by sandflies. On the Indian
subcontinent (ISC), VL is targeted for elimination as a public health problem by 2017. In the context of VL, the
elimination target is defined as an annual VL incidence of <1 per 10,000 capita at (sub-)district level. Interventions
focus on vector control, surveillance and on diagnosing and treating VL cases. Many endemic areas have not yet
achieved optimal control due to logistical, biological as well as technical challenges. We used mathematical
modelling to quantify VL transmission dynamics and predict the feasibility of achieving the VL elimination target
with current control strategies under varying assumptions about the reservoir of infection in humans.
Methods: We developed three deterministic age-structured transmission models with different main reservoirs of
infection in humans: asymptomatic infections (model 1), reactivation of infection after initial infection (model 2),
and post kala-azar dermal leishmaniasis (PKDL; model 3). For each model, we defined four sub-variants based on
different assumptions about the duration of immunity and age-patterns in exposure to sandflies. All 12 model
sub-variants were fitted to data from the KalaNet study in Bihar (India) and Nepal, and the best sub-variant was
selected per model. Predictions were made for optimal and sub-optimal indoor residual spraying (IRS) effectiveness
for three different levels of VL endemicity.
Results: Structurally different models explained the KalaNet data equally well. However, the predicted impact of IRS
varied substantially between models, such that a conclusion about reaching the VL elimination targets for the ISC
heavily depends on assumptions about the main reservoir of infection in humans: asymptomatic cases, recovered
(immune) individuals that reactivate, or PKDL cases.
Conclusions: Available data on the impact of IRS so far suggest one model is probably closest to reality (model 1).
According to this model, elimination of VL (incidence of <1 per 10,000) by 2017 is only feasible in low and medium
endemic settings with optimal IRS. In highly endemic settings and settings with sub-optimal IRS, additional
interventions will be required.
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Background
On the Indian subcontinent (ISC), visceral leishmaniasis
(VL) is caused by the protozoan Leishmania donovani,
which is transmitted by the peri-domestic female sand-
fly, Phlebotomus argentipes. VL is a neglected tropical
disease (NTD) [1] with about 300 million people at risk
globally, mainly affecting the poorest of the poor in rural
areas. Two thirds of the estimated global 200,000 to
400,000 new VL cases per year occur on the ISC [2].
Furthermore, over 20,000 deaths per year on the ISC are
attributed to VL, making it the deadliest parasitic
infection in the world after malaria [3, 4]. Humans are
considered the only host for L. donovani on the ISC,
whereas in the rest of the world VL is both anthropono-
tic and zoonotic, and can also be caused by L. infantum
[3]. Only a small fraction of the people that become in-
fected develop clinical symptoms, while most remain
asymptomatic, nonetheless carrying the parasite [5].
People that develop symptoms of VL, also known as
kala-azar (KA), display signs of fever, weight loss,
anaemia and splenomegaly, and eventually die if left
untreated [6, 7]. It is estimated that about one to five
percent of successfully treated VL cases on the ISC
develop post-kala-azar dermal leishmaniasis (PKDL), a
self-healing skin disease which may last for several years
[8–10]. L. donovani infection can be diagnosed by –
among other methods –testing of peripheral blood for
parasite DNA by means of polymerase chain reaction
(PCR), and by testing for antibodies using the direct
agglutination test (DAT, a marker for humoral immune
response indicating current or recent infection).
Even though attention for VL has grown over the past
decade, its transmission dynamics are still not com-
pletely understood. For instance, little is known about
the role and duration of acquired immunity after infec-
tion, the infectiveness of different disease stages towards
the sandfly, and natural sandfly behavior. The observa-
tion of low and infrequent numbers of symptomatic VL
cases, which by themselves are not sufficient to sustain
transmission, suggests the presence of a parasite reser-
voir, which is also supported by high proportions of PCR
+ individuals [11]. Even though the parasite has been
found in domestic animals, their role in transmission on
the ISC has not been established [12], and therefore
humans remain the only confirmed reservoir of the
parasite on the ISC. Potential human reservoirs of infec-
tion (apart from the low number of symptomatic cases)
are asymptomatic infections, persons in whom a past
infection reactivates, PKDL cases, or a mixture of these.
In 2012, WHO developed the first NTD 2020 Roadmap
that contains targets for the elimination and control of VL
[13]. That same year, the London Declaration was signed
by several partners from the public and private sector, to
support the 2020 WHO Roadmap targets through
advocacy, pharmaceutical supplies and research funding
[14]. On the ISC, the target is to eliminate VL as a public
health problem by or before the end of 2017, where
elimination is defined as an annual incidence of VL of <1
per 10,000 capita at sub-district-levels in Bangladesh and
India; and at district-level in Bhutan and Nepal [15]. In
the rest of the world, the WHO target is 100 % detection
and treatment of all VL cases. In the ideal situation of
meeting the WHO targets for VL, the global impact
(relative to the counterfactual had the pre-control
situation in the year 1990 continued unabated) has been
estimated at 2.4 million averted deaths, 140 million
averted DALYs, and about 20 billion US dollars saved
between 2011 and 2030 [16, 17].
The governments of the ISC-countries have committed
themselves to achieving the elimination target by imple-
menting different interventions. These are mainly focused
on two approaches: (1) early diagnosis of symptomatic
cases followed by effective case management, which pre-
vents disability and death, and reduces the presence of in-
fective individuals; and (2) vector control to reduce or
interrupt transmission [3]. Indoor residual spraying (IRS)
of human dwellings and cattle sheds with long lasting in-
secticides such as DDT is currently the most important
and widely implemented form of vector control. To a
lesser extent, insecticide–treated bed nets, environmental
management and personal protection are also being imple-
mented [18, 19]. Although indoor spraying campaigns on
the ISC have been scaled up over the last years, not all
regions have yet achieved effective IRS programs due to
various challenges such as limited training of spraying
teams, poor community acceptance, sandfly resistance to
DDT, and the peri-domestic lifestyle of the sandfly [19–24].
Here, we focus on the following research question: is it
technically feasible to achieve the WHO VL elimination
targets on the ISC by 2017 with current IRS strategies
and ongoing detection and treatment of cases? To this
end, we upgraded the most relevant existing determinis-
tic VL transmission model [25, 26], and developed three
age-structured deterministic models representing three
potential main parasite reservoirs in humans: (1) asymp-
tomatic cases, (2) recovered (immune) individuals in
whom infection reactivates, and (3) cases of PKDL. For
each model, we defined four sub-variants with different
transmission dynamics: fixed or age-dependent sandfly
exposure and a duration of the late recovered ‘immune’
stage of two or five years. All twelve models were quan-
tified using data from the KalaNet study in Bihar (India)
and Nepal [27, 28]. With the best sub-variant of each of
the three models, we simulated the impact of IRS (opti-
mally and sub-optimally implemented) on VL incidence
for three endemic settings to predict the feasibility of
achieving the elimination target of <1 VL case per
10,000 capita per year on the ISC.
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Methods
Model structure
We developed a set of three VL transmission models,
each with four sub-variants, based on the general struc-
ture of a previous model developed by Stauch and col-
leagues at Tuebingen University [25, 26]. In all models
(see Fig. 1 for schematic representation), we assume that
humans are born susceptible and, when bitten by an in-
fective sandfly, will move to the stage of early asymp-
tomatic infection. We assume that individuals in this
stage test positive for parasite DNA using PCR (PCR+),
and test negative for antibodies using the direct agglutin-
ation test (DAT-). After some time, an infected person
will develop antibodies and advance to the stage of late
asymptomatic infection (PCR+/DAT+). A small fraction
of cases with late asymptomatic infection will develop
symptoms of VL and enter the stage of symptomatic un-
treated (PCR+/DAT+). While most symptomatic cases
will require one or two treatment regimens (stages of
first-line and second-line treatment (PCR+/DAT+), initi-
ated after a detection delay) to clear infection to the ex-
tent that parasite DNA is no longer detectable
(putatively recovered stage, PCR-/DAT+), a small frac-
tion of untreated symptomatic cases will spontaneously
clear infection and directly advance to the putatively re-
covered stage (i.e. non-fatal symptomatic cases that do
not turn up in surveillance data because of low severity
of disease) [29]. All symptomatic cases are assumed to
be at excess risk of dying from VL, with the excess risk
being highest in untreated cases. From the putatively
recovered stage, a small fraction of individuals may
develop PKDL (PCR+/DAT+) from which they will
eventually recover (spontaneously or with treatment; the
exact mechanism of recovery is not specified in the
model). However, the majority of cases in the putatively
recovered stage advance to the early recovered stage
(PCR-/DAT+), along with recovered cases of PKDL, and
the majority of late asymptomatic infections that do not
develop any symptoms and spontaneously clear infection
to the extent that parasite DNA is no longer detectable.
Eventually, individuals in the early recovered stage will
lose their DAT positivity, and enter the late recovered
stage (PCR-/DAT-), during which they are still immune
to new infections. From there, individuals either lose
their immunity and become susceptible again to infec-
tion through exposure to infective sandflies (model 1),
or their past infection reactivates such that they re-enter
the stage of early asymptomatic infection without requir-
ing exposure to an infective sandfly (model 2). Model 2
presents a hypothetical but biologically plausible scenario,
for example when individuals experience decreased
immune-competence during malnutrition or co-infection
(e.g. HIV) [30]. In terms of structure, model 1 is the most
similar to the model by Stauch et al. [25].
In each model, infection is transmitted between
humans by bites of female sandflies (we do not consider
male sandflies, which only feed on plant sugars). We
define the sandfly population in terms of sandflies per
human, a quantity that incorporates sandfly density, the
unknown ratio of blood meals taken on human and ani-
mals, and the unknown (average) vector competence of
sandflies. The sandfly population is partitioned into 3
compartments; all sandflies are born susceptible and after
feeding on an infective human, they become infected with
some probability depending on the infectiveness of the
human stage of infection. After an incubation period,
infected sandflies become infective and may infect
susceptible humans. We assume no excess mortality
among infected sandflies. IRS is assumed to reduce
the sandfly density and consequently, human exposure
to sandfly bites.
In models 1 and 2, all PCR+ human stages (asymp-
tomatic and symptomatic infection, and PKDL) are
considered to be infective towards sandflies, with early
asymptomatic cases being half as infective as late asymp-
tomatic cases (as assumed by Stauch et al. [25]). Infec-
tiveness of untreated clinical cases is set at 1.0, treated
patients and PKDL have an infectiveness of 0.5, and that
of asymptomatic cases is estimated. In model 3, which is
identical in structure to model 1, only cases of symp-
tomatic infection and PKDL are assumed to contribute
to transmission [31], with PKDL having a higher (esti-
mated) infectiveness than in models 1 and 2. Further, in
model 3 we set the duration of PKDL to thrice as long
as in model 1, based on expert opinion, assuming that
there is a larger spectrum of PKDL severities than
currently recognized, of which undiagnosed forms also
contribute to transmission. Model 3 can be considered an
extreme variant of model 1. A model variant in which only
symptomatic human cases (VL and regular PKDL) are in-
fective towards the sandfly, could not be fitted to data on
the infection prevalence in sandflies under the assump-
tions of an endemic equilibrium and homogeneous mixing
of human and sandfly populations (Additional file 1, sec-
tion 5). This indicates that, in order to meet the infection
prevalence in sandflies (Table A1-2 in Additional file 1,
section 3), there has to be an additional reservoir of infec-
tion in humans that are PCR+, which could be in asymp-
tomatic individuals (models 1 and 2), or in long lasting
PKDL cases (model 3).
The transmission model was defined in terms of a
system of ordinary differential equations (ODE; see
Additional file 1, section 2). Hence, we assumed that all
transitions between stages take place at constant rates,
leading to exponentially distributed durations of stages.
However, because the human demography on the ISC
cannot be well approximated by the assumption of a
stable human population size and exponential human
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Fig. 1 (See legend on next page.)
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survival (as applied by Stauch et al.), we allowed for
human population growth and age-specific human mor-
tality (i.e. by stratifying the system of ODEs into annual
age categories). The number of sandflies per human is
assumed to be stable during human population growth
and in absence of vector control.
Parameter quantification
Assumptions about human demography, excess mortal-
ity, duration of symptomatic stages of infection, and
sandfly biology were based on literature and published
data sources (Table 1) [25, 32–39]. Note that for model
3, the duration of PKDL is assumed to be 15 years in-
stead of 5 years (models 1 and 2). Next, for each model
we defined four sub-variants in terms of assumptions
about the duration of the late recovered stage and age-
patterns in exposure to sandfly bites. The duration of
the late recovered stage was chosen to be two or five
years, which were reasonable values, given that the ana-
lytical solution of the system of ODEs at equilibrium
showed that all three models could only support the data
for durations of the late recovered stage less than seven
years (Additional file 1, section 5). With regard to age-
patterns in exposure to sandfly bites, we assumed that
exposure is either fixed, or increases proportionally with
body surface area (i.e. a linear increase in sandfly expos-
ure between age 0 to 20 followed by a constant exposure
from age 20 onwards). The latter assumption has also
been previously used to model the vector-borne diseases
onchocerciasis and lymphatic filariasis [40–42].
Remaining model parameters (sandflies per human,
duration of asymptomatic stages of infection, infective-
ness of human stages of infection, and proportion of
asymptomatic infections that develop symptoms of VL)
were estimated based on data from the KalaNet study, a
community-based intervention trial in hyper-endemic
clusters in Bihar, India, and in the Terai plains in Nepal
[27, 28, 43]. The KalaNet data constitute cross-sectional
information on DAT status of 21,204 individuals from
three time points spanning two years, and information
on incidence of VL during the entire two-year study
period. For 668 individuals aged 14 and older, PCR
testing was performed as well. Further, a subset of
individuals were covered in consecutive cross-sectional
surveys, allowing derivation of changes in PCR and DAT
status. To quantify our model, we used prevalence of
DAT-positivity (titre > 1:800, like Stauch et al. [25]),
PCR-positivity, PCR andDAT-positivity, incidence of VL
and incidence of PCR-positivity (i.e. a change from PCR-
negative to positive between two consecutive years), and
the prevalence of L. donovani in sandflies in Nepal [43]
(which in the model we take to be the proportion of
sandflies that is infective, like Stauch et al. [25]). An
overview of these data is provided in Table A1-2 in
Additional file 1, section 3. In the main analysis, we
assume that observed levels of PCR and DAT-positivity
adequately reflect prevalences of the corresponding
stages of infection in our model. The importance of
imperfect test sensitivity and specificity was explored
using analytical solutions of the equilibria of the system
of ODEs (Additional file 1, section 5). We fitted model
parameters to country-specific, population-level data,
aggregated over years, villages, age, and sex. Because we
used an age-structured model, we could take account of
the fact that the PCR data were sampled from a sub-
population aged 14 years and older, while data on DAT-
positivity and VL incidence were sampled from the
whole population (in contrast to Stauch et al. [25], who
analyzed the KalaNet data as one homogeneous entity).
Model parameters were fitted in two steps. First, we
quantified model parameters with regard to duration of
stages of asymptomatic infection, fraction of asymptom-
atic cases that develop VL, and the number of sandflies
per human, conditional on preliminary assumption
about infectiveness of human stages of infection (which
is only determined by the prevalence of infection in
sandflies, and can therefore be solved separately, see
Additional file 1). The system of ODEs was solved
numerically using the deSolve package [44] in R (version
3.2.0) [45], and parameters were estimated within a
maximum likelihood framework (ignoring the clustered
study design, just like Stauch et al. [25]), using the BFGS
algorithm from the optim package. Prior to every evalu-
ation of the optimization algorithm we let the model
reach equilibrium, assuming that the KalaNet data rep-
resent an equilibrium situation. Second, we analytically
solved the system of ODEs with regard to infectiveness
of human stages of infection and the number of sandflies
per human, given data on prevalence of infection in
sandflies in Nepal (for approach, see Additional file 1).
The proportion of putatively recovered cases that
develop PKDL was set to 5 % such that the predicted
PKDL prevalence for endemic villages in Nepal in
models 1 and 2 was 5 per 10,000 population, which
(See figure on previous page.)
Fig. 1 Schematic representation of three model structures. In model 1 (a), recovered individuals eventually lose their immunity and become
susceptible again to infection through exposure to infective sandflies. In model 2 (b), recovered individuals may experience reactivation of their past
infection such that they directly re-enter the stage of early asymptomatic infection without requiring exposure to infective sandflies. In model 3, which
is identical in structure to model 1 (c), only cases of symptomatic infection and PKDL contribute to transmission of infection, and duration of PKDL is
three times as long as in model 1
Le Rutte et al. Parasites & Vectors  (2016) 9:24 Page 5 of 14
corresponds to the 4.4 to 7.8 per 10,000 that has
been reported for Nepal [10]. Last, for each model we
selected the best sub-variant based on the log-
likelihood with regard to age-patterns in prevalence
of infection markers and incidence of VL and PCR-
positivity.
Predicting the impact of IRS
With each best sub-variant of model 1, 2, and 3, we sim-
ulated a high, medium, and low endemic setting, defined
in terms of pre-IRS VL incidence of 20 per 10,000, 10
per 10,000 and 5 per 10,000 per year, respectively. These
endemic settings were chosen given the declining trends
in VL cases and the fact that VL incidences of 20 cases
per 10,000 capita per year (as observed in the KalaNet
setting) are currently rarely observed [46, 47]. Each
endemic setting was quantified by tuning the number
of sandflies per human, assuming that transmission
dynamics are in equilibrium with current detection and
treatment interventions (which are slightly different
from those in the KalaNet situation; see Table 1). We
simulated the impact of IRS strategies as planned for
India, i.e. two spraying rounds per year targeting houses
and cattle sheds in endemic villages [18]. We assumed
that optimally implemented IRS (optimal IRS) results in a
continuous reduction in sandfly density of approximately
63 %, given the reported reduction in sandfly density after
IRS with dichlorodiphenyltrichloroethane (DDT) of 72 %
[48] and the assumption that rotating spraying teams
continuously cover households 85 %-95 % of the time.
Sub-optimally implemented IRS (sub-optimal IRS) was
assumed to be half as effective due to lower continuous
household coverage, sub-optimal spraying techniques and
sandfly resistance to DDT [19–23], leading to a continu-
ous sandfly density reduction of 31.5 %. We interpreted
the WHO elimination target in our model as an annual
incidence of VL cases (receiving treatment) of <1 per
10,000 capita.
Table 1 Overview of assumptions and pre-set parameters
Parameters Valuea Source
Human birth rate (per 1000 capita, αH) 21 (Indian crude birth rate in 2011) [32]
Human mortality rate (μH) Age-dependent (Indian mortality rates in 2011) [33]
Average duration of late recovered stage (years, 1/ρRHC) 2 or 5 Pre-set
Average duration of symptomatic untreated stage (days, 1/ρIHS) 30 (fitting) and 45 (predicting) Unpublished data
Average duration of symptomatic treatment 1 (days, 1/ρIHT1) 30 (fitting) and 2.5 (predicting) [34]
Average duration of symptomatic treatment 2 (days, 1/ρIHT2) 30 (fitting) and 10 (predicting) [35]
Average duration of putatively recovered stage (months, 1/ρIHT) 21 [36]
Average duration of PKDL (years, 1/ρIHL) 5 (models 1 and 2) and 15 (model 3) Expert opinion (EH and MB)
Infectiveness of symptomatic untreated cases (pIHS) 1.0 Reference value
Infectiveness of patients under treatment 1 and 2 (pIHT1, pIHT2) 0.5 Expert opinion (EH and MB)
Infectiveness of PKDL cases (pIHL) 0.5 (models 1 and 2 only; estimated for model 3) Expert opinion (EH and MB)
Fraction of untreated symptomatic cases that spontaneously,
putatively recover (fp)
0.03 [25]
Excess mortality rate among untreated symptomatic cases
(per day, μK)
1/150 Assumption
Excess mortality rate among treated symptomatic cases
(per day, μKT)
1/150 + 1/600 = 1/120 (fitting) and 1/150 (predicting) [34, 35]
Fraction of failed first-line treatments (fF) 0.05 [37]
Fraction of putatively recovered cases that develop PKDL (fL) 0.05 (set such that models 1 and 2 predicted a
prevalence of PKDL between 4.4 and 7.8 per
10,000 capita in India)
[10, 38]
Average life expectancy of the sandfly (days, 1/μF) 14 [39]
Average duration of incubation period in sandflies (days, 1/ρEF) 5 [62]
Sandfly biting rate (per day, β) 1/4 [63]
Transmission probability sandfly to human (pH) 1.0
b Reference value
The parameter values listed here are the same for all three models and their sub-variants, unless indicated otherwise
aParameter values marked with “fitting” only apply to the KalaNet study setting and were therefore only used when fitting the models to the KalaNet data; related
to this, different parameter values were used when predicting the impact of IRS (indicated by “predicting”)
bThe probability that a susceptible person becomes infected when bitten by an infectious sandfly is assumed to be 1; potential overestimation is compensated by
the estimated sandfly density per human
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In a sensitivity analysis for predicted trends in VL
incidence during IRS, we varied the values of key
estimated and assumed parameter values by factors
4/5 and 5/4 (except for the number of sandflies per
human, as this parameter mainly influences pre-
dicted trends in VL incidence through pre-IRS infec-
tion levels).
Results
All four sub-variants of all three models could closely re-
produce the country-specific, population-level incidence
and prevalence data, with deviances ranging between
2.11 and 2.61 9 (χ2 degrees of freedom = 8, p > > 0.5). All
model sub-variants estimated the duration of early
asymptomatic infection (PCR+/DAT-) at around 1.1 years
and the duration of late asymptomatic infection (PCR
+/DAT+, excluding cases with symptoms) at just under
four months. Estimates for the proportion of asymptom-
atically infected cases that develop VL (range 2.8–3.9 %),
infectiveness of early and late asymptomatic infection
(0.014–0.018 and 0.027–0.035, respectively, model 1 and
2 only), infectiveness of PKDL (2.32–2.72, model 3 only),
and duration of the early recovered stage (1.0 to
1.7 years; PCR-/DAT+, excluding putatively recovered
people) slightly varied between models and sub-variants
(i.e. assumptions about age-dependent exposure to
sandfly bites and duration of the late recovered stage).
All fitted parameter values are presented in Table 2.
Given the parameter estimates above, the most common
infection history for a person to go through (susceptible,
asymptomatically infected, and early recovered without
ever developing VL) takes on average about 2.7 to 3.1 years
(not including the duration of the late recovered stage,
which we assume to be either two or five years). This
is in line with the observation that only 6 out of 668
subjects who were tested with PCR were positive in
year 1, negative in year 2, and again positive in year
3. All three models predicted that in a state of
endemic equilibrium about 10 % of all transmission
of infection is generated by VL cases (treated and un-
treated). According to models 1 and 2, an additional
8 % of transmission is generated by PKDL cases and
the remaining 82 % by asymptomatically infected
cases. In model 3, 90 % of transmission is generated
Table 2 Quantified parameter values of the twelve model variants
The colours represent the model sub-variants that best reproduced the age-structured prevalence and incidence data. See Additional file 2 for illustrations
of fitting of all model variants to all data and Fig. 2 for the predicted and observed age-patterns in VL incidence and DAT prevalence in India and Nepal
with the selected model variants
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by PKDL cases (and none by asymptomatic infections,
by default).
The sub-variants of models 1 and 3 that best repro-
duced the age-specific data were based on the assump-
tions of age-dependent exposure to sandflies and a
duration of late recovered stage of two years; for model
2, the sub-variant with fixed exposure to sandflies and
duration of the late recovered stage of five years best
fitted the data. Figure 2 illustrates the fit of the best sub-
variants to the age-specific data on VL incidence and
DAT prevalence, with identical fits for model 1 and 3.
Fits to other data types (PCR incidence, PCR prevalence,
PCR/DAT prevalence) and fits for all model sub-variants
can be found in Additional file 2.
Using the best sub-variant of each model, we predicted
the impact of optimal and sub-optimal IRS on VL inci-
dence for high, medium and low endemic settings
(Fig. 3). Models 1 and 3 predict that optimal IRS (63 %
assumed reduction in sandfly density) reduces VL inci-
dence by about 25 % in the first year and by another
25 % of the original incidence level in the second year
after the start of IRS, irrespective of the endemicity level
at equilibrium. However after two years, the predictions
of model 1 and 3 diverge: in model 1, VL incidence
keeps on declining due to the rapid depletion of the
reservoir of infection in asymptomatically infected cases
(average duration of asymptomatic infection of about
1.4 years); in model 3, the reduction in VL incidence
slows down strongly after two years due to the presence
of the relatively large reservoir of infection in PKDL-
cases (average duration of 15 years). Model 2 predicts a
relatively slow and stable decline from the start of IRS,
as the decrease in sandfly density is assumed to have no
influence on VL cases arising from people in whom old
infection reactivates.
Model 1 predicts that about 4 to 6 years of optimal
IRS will reduce the annual VL incidence in low and
medium endemic settings to levels (just) under 1 per
10,000 capita. However, models 2 and 3 predict that
these low levels of VL incidence cannot even be
achieved within 12 years of optimal IRS. Similarly, model
1 predicts that with sub-optimal IRS, these levels of VL
incidence are only achieved after about 10 years, and only
in low endemic settings. Still, when IRS is continued over
an extremely long period of time (say 200 years), most
sub-variants of the three models predict that optimal IRS
Fig. 2 Predicted and observed age-patterns in VL incidence and DAT prevalence in India and Nepal. Coloured lines represent model predictions
from the sub-variant of each of the three models that best fit age-patterns in human infection markers; black bullets represent the data per age
group; horizontal lines indicate the age range for each data point; vertical lines represent 95 %-Bayesian credible intervals, given total raw sample sizes
(i.e. not accounting for clustering, see Additional file 1 for sample sizes). See Additional file 2 for illustrations of the fit of all model sub-variants to all
data types
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will eventually result in elimination in all endemic settings
(Additional file 3). Sub-optimal IRS will only lead to
reaching the target in low and medium endemic settings,
with varying durations of IRS required per model.
Additional file 3 also illustrates that for model 1 (and 3 to
a lesser extend), the predictions depend on the duration of
the late recovered stage in high endemic settings and with
sub-optimal IRS: longer (5 year) duration leads to a slower
decline in VL incidence, and a faster re-occurrence of in-
fection. For model 2, the duration of the late recovered
stage on the impact of IRS is negligible. For model 3, the
deceleration of the decline in VL incidence is largely a
function of the duration of PKDL. A longer duration of
PKDL will generate a longer infection pressure towards
the sandfly and therefore slow down the decreasing VL
incidence.
Figure 4 illustrates trends in prevalence of infective
sandflies (among caught sandflies) for a medium
endemic setting with optimal IRS (see Additional file 4
for low and highly endemic settings). Compared to
model 1, models 2 and 3 predict a relatively slow decline
in prevalence of infective sandflies because of the per-
sisting parasitic reservoirs of late recovered and PKDL
cases, respectively.
Additional file 5 provides an overview of the results of
the sensitivity analysis for a medium endemic setting
with optimal IRS. Only the assumed effect of IRS (high
and low values were 5/4 and 4/5 of the value used in the
main analysis) directly influenced predicted trends with-
out changing pre-control infection levels. The duration
of IRS required to achieve the elimination target (only
relevant in model 1) was most sensitive for the param-
eter values of the effect of IRS (4 and 9 years until
elimination), the duration of the early asymptomatic
stage of infection (4 and 8.5 years until elimination), and
the proportion of infections that result in symptoms (4.5
and 8 years until elimination). Sensitivity of predicted
trends in VL incidence during IRS were strongly associ-
ated with changes in pre-control infection levels (i.e.
alternative parameter values often produced parallel
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Fig. 3 Predicted impact of optimal and sub-optimal IRS on VL incidence for three endemic settings. IRS is assumed to start in the year zero. Lines
within plots represent different pre-IRS endemic settings (high: 20/10,000, medium: 10/10,000, low: 5/10,000); the dotted line represents the target
VL incidence of <1 per 10,000 capita. Model predictions were made with the sub-variant of each of the three models that best fit age-patterns in
human infection markers. See Additional file 3 for the short and long-term impact of optimal and sub-optimal IRS in low, medium, and highly
endemic settings with all model sub-variants
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trends in VL incidence). The predictions by model 3
were most sensitive to the proportion of individuals
developing symptoms and PKDL, and the infectiveness
and duration of PKDL (illustrated in Additional file 5).
The transmission dynamics are insensitive to the as-
sumed infectiveness of early asymptomatic cases relative
to late asymptomatic cases (data not shown).
Discussion
We developed three structurally different models with
different reservoirs of infection to predict the impact of
IRS on VL incidence on the ISC, using the KalaNet
dataset from India and Nepal to quantify transmission
dynamics in each model. All three models could explain
the KalaNet data equally well. However, the predicted
impact of IRS varied substantially between models, such
that a conclusion about reaching the VL elimination
targets for the ISC heavily depends on assumptions
about the main reservoir of infection in humans: asymp-
tomatic cases (model 1), recovered (immune) individuals
in whom infection reactivates (model 2), or PKDL cases
(model 3). Biologically, a mixture of the different models
is most likely, but could not be quantified solely based
on the KalaNet data. Still, given that the three models
predict markedly different trends of VL incidence and
infection in sandflies during IRS, we may be able to
express preference for one of the models based on field
data regarding the impact of IRS.
So far, only a limited amount of field data on the
impact of IRS on VL incidence has been published [49].
Kumar et al. report that after one year of active IRS in 19
districts of Bihar, VL incidence decreased by 49–100 % in
15 districts, and VL incidence was stable or even increased
in 4 districts, such that the average reduction in VL preva-
lence over all 19 districts was about 50 %. Based on these
findings we tentatively conclude that the models with the
infection reservoir in asymptomatic cases (model 1) and
PKDL cases (model 3) are probably closer to reality than
the model with the disease reservoir in re-activating
recovered cases (model 2). Although there is literature on
prevalence of infection in sandflies [43, 50, 51] and the im-
pact of IRS on sandfly density [20, 21, 52], unfortunately,
there are no published data on the impact of IRS on
prevalence of infection in sandflies. Such data would be
very valuable to further our understanding of VL trans-
mission dynamics, and distinguish between model 1 and 3
the model that is closest to reality. Still, as model 3 was
included as an extreme variant of model 1, we consider
model 1 to be the most realistic of our set of models.
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Fig. 4 Predicted prevalence of infective sandflies during IRS. Pre-IRS prevalence levels of infective sandflies represent a setting with 10 annual VL
cases per 10,000 capita. IRS is assumed to start in the year zero, and to be implemented optimally (63 % reduction in sandfly density). The three
colored lines represent the sub-variant of each of the three models that best fit age-patterns in human infection markers. See Additional file 4 for
low, medium and highly endemic settings with optimal and sub-optimal IRS
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that is taking place in Bihar India, [53] are anticipated to
provide more data on the long-term impact of IRS on VL
incidence and perhaps prevalence of infected sandflies in
the field, which will be crucial to validate model predic-
tions and better understand VL transmission dynamics.
The large scale implementation of IRS with DDT in
India started in 2005 as part of the national VL elimin-
ation program [54], twelve years before the targeted year
of VL elimination, 2017. Assuming that model 1 is
closest to reality, elimination of VL (incidence <1 per
10,000 capita) is feasible in low, medium and highly en-
demic settings by means of about four, six and twelve
years of optimal IRS, respectively. With sub-optimal IRS,
which in some settings may still be too optimistic, model
1 predicts that the elimination target can only be
achieved in low endemic settings within about 10 years.
Assuming that in some highly endemic areas IRS was
only implemented after the release of the WHO NTD
Roadmap and London Declaration in 2012, IRS would
have to reduce sandfly densities by at least about 85 %
to achieve the elimination target in the following 5 years
(by 2017). With our assumed 63 % reduction in sandfly
density by optimal IRS, the elimination target can be
achieved within 5 years (i.e. by 2017 if IRS was only
implemented in 2012) for settings with an annual VL in-
cidence of up to about 8 per 10,000 capita. The outlook
would be much poorer if IRS actually has been imple-
mented sub-optimally. In particular for areas with highly
endemic levels, a longer period and/or higher effective-
ness of IRS will be required, ideally supplemented by
additional interventions, certainly if the level of IRS is
sub-optimal. DDT is interpreted to have an insecticidal
effect on the sandfly; an insect-repellent effect would
have led to a decreased biting rate, with a relatively
lower impact on the transmission and VL incidence In
the future, the use of DDT is expected to be phased out
and replaced by synthetic pyrethroids, due to the in-
creasing sandfly resistance to DDT [23] and its negative
environmental impact [55]. In the further future, vaccin-
ation may be an important additional tool to eliminate VL
on the ISC, should a vaccine become available [56, 57].
Our models provide a tool to explore the potentional
impact of future vaccines and identify the target
product profiles of vaccines that may achieve the
elimination target.
Our study is based on the existing deterministic trans-
mission model that was developed at Tuebingen University
by Stauch et al. [25], but we considerably improved the
model in several ways. To better account for the human
demography on the ISC, we added population growth and
age-specific mortality. The resulting age-structured model
further allowed us to better mimic age-patterns in the
KalaNet data. This also allowed us to account for the fact
that the PCR data in the KalaNet study were collected
from a subsample of individuals aged 14 and older. Unlike
Stauch et al., we purposely did not use data on leishmanin
skin testing (LST, which was associated with the late recov-
ered, immune stage), as these LST data did not originate
from the same study area. Moreover, the fraction LST posi-
tive used and the assumption that early asymptomatic
infection (PCR+/DAT-) lasts only 60 days (we estimate 1.1.
year) caused the original model to predict a very short nat-
ural history of infection; one cycle of asymptomatic infec-
tion, recovery, and loss of immunity was predicted to only
take about 450 days, on average. Instead, we chose plaus-
ible values for the duration of the recovered, immune stage
(two or five years, which could readily support the data as
shown by the solutions to the system of ODEs in equilib-
rium), and used data on PCR incidence and prevalence of
PCR and DAT-positivity to inform the model about the
duration of the natural history of asymptomatic infection.
We further improved the model by fitting our models to
country-specific data (India vs. Nepal), and by taking
account of the fact that the data on prevalence of infection
in sandflies was only collected in Nepal.
Although our model was based on detailed field data,
several uncertain factors remained. We interpreted the
KalaNet dataset as if it represented an endemic equilib-
rium. However, in reality repeating small outbreaks of
symptomatic cases have been reported to occur [58].
Whether these fluctuations are true outbreaks or simple
stochastic variation remains to be clarified, which will
require more modelling and detailed longitudinal data.
We will investigate this in the future, using an
individual-based model (based on the current study) that
captures both stochastic and spatial variation. In our
analyses, we assume that the KalaNet data represent an
endemic equilibrium, which is reasonable given the slow
transmission dynamics in all three models; this slowness
is not a result of the equilibrium assumption, but due to
the large and stable reservoir of infection in asymptom-
atic individuals (model 1), reactivating past infections
(model 2), or PKDL cases (model 3). The KalaNet study
included an active case-finding strategy, and although
we accounted for a longer duration of the symptomatic
untreated stage for our predictions, 45 instead of 30 days,
the time between onset of symptoms and treatment
could in certain settings be longer. This resulted in an
increase in the number of predicted deaths due to VL
but hardly influenced the transmission dynamics or the
predicted duration until reaching the elimination target.
Another potential limitation of our study is that ob-
served levels of PCR and DAT-positivity were assumed
to adequately reflect the prevalences of the correspond-
ing stages of infection in the model. In a meta-analysis,
Chappuis et al. found that sensitivity and specificity of
DAT testing for the diagnosis of VL were fairly high
(about 97.1 % and 95.7 % respectively)" [59], but these
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estimates do not necessarily apply to the ascertainment
of L.donovani asymptomatic infection, as the DAT test
was not validated as such for that purpose. Further, we
interpreted the DAT data at the 1:800 titre cut-off
(instead of the standard cut-off of 1:1600), which prob-
ably increased test sensitivity but decreased specificity.
There is little information regarding the sensitivity and
specificity of PCR, as there is no gold standard [60]. An
exploratory analysis of accounting for imperfect DAT
and PCR testing in fitting the KalaNet data showed that
predictions for the impact of IRS only vary marginally
when using realistic values of sensitivity and specificity
(Additional file 1, section 5). Further, the duration of the
early asymptomatic stage suggests that the development
of detectable antibodies after infection requires about
1 year, which seems relatively long. However, the esti-
mated duration of the early asymptomatic stage was only
at most 7 % lower when sensitivity of PCR testing was
assumed to be as low as 70 %. This can be explained by
the fact that PCR sensitivity affects PCR prevalence and
incidence in the same way (although the effect on inci-
dence is somewhat larger due to the involvement of two
measurements). Our estimate of the duration of immun-
ity after clearance of infection (approximately 3 years, of
which two year were assumed to be spent in a DAT-
negative state), is very similar to that by Chapman et al.
[61], who recently analysed rK39 and LST data from
Bangladesh using a Markov model. There are differences
in the estimates of the duration of the of asymptomatic
stage: 5 months (Chapman et al.) and 1.5 years in this
study, and the percentage of asymptomatic individuals
that develop clinical symptoms: 14.7 % (Chapman et al.)
and 3.3 % in this study. These differences may be well
explained by differences in the type of data (geographic
region and type of diagnostic tests) and modelling
methods used (the use of a full transmission model is
the strength of the current study). Lastly, we could only
estimate infectiveness of human stages of infection indir-
ectly from the prevalence of infection in sandflies, and
only after certain assumptions about the relative infec-
tiveness of clinical cases. Ongoing xenodiagnostic studies
and additional longitudinal data on the prevalence of in-
fection in sandflies during interventions are anticipated
to further inform the model regarding this aspect.
Conclusions
We conclude that several structurally different models
can explain population-level data on VL transmission
equally well. Consequently, the predicted impact of IRS
strongly depends on assumptions about the reservoir of
infection in humans. Data on the impact of IRS available
so far suggest one model is probably closest to reality
(model 1, where asymptomatic individuals represent the
main reservoir of infection). According to this model,
elimination of VL (incidence of <1 per 10,000 capita) is
probably only feasible by 2017 in low and medium
endemic settings with optimal IRS; in highly endemic
settings and settings with sub-optimal IRS, additional
interventions will be required.
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